Abstract
Background: Psoriasis is a chronic, autoimmune dermatologic disease that often requires systemic treatment. Of the immune regulating therapies, methotrexate (MTX) is a commonly used systemic therapy. Both MTX and psoriasis are associated with an increased risk of developing nonmelanoma skin cancers (NMSCs). Currently, the risk associated with combining these factors is not well quantified.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
